BeiGene Ltd

Research BeiGene Ltd (ONC) on Bullrun: valuation model: 28.2% overvalued, market cap USD 30.09B, P/E 64.7. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerONC
• ExchangeNASDAQ
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal28.2% overvalued
• Market capUSD 30.09B
• P/E64.7
• Financial periodFY2025
• RevenueUSD 5.34B
• Revenue growth40.2%
• Net incomeUSD 286.93M
• Free cash flowUSD 941.74M
• Gross margin87.5%

Valuation Snapshot

Bullrun's latest valuation model marks BeiGene Ltd as 28.2% overvalued; latest market cap is USD 30.09B; P/E is 64.7.

About BeiGene Ltd

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers;

Frequently asked questions

Is BeiGene Ltd overvalued or undervalued?

Bullrun's valuation model currently marks BeiGene Ltd as 28.2% overvalued.

What is BeiGene Ltd's market cap?

BeiGene Ltd's market capitalization is USD 30.09B.

What is BeiGene Ltd's P/E ratio?

BeiGene Ltd's price-to-earnings (P/E) ratio is 64.7.

What does BeiGene Ltd do?

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.